Artificial Intelligence (AI)

Mobile health applications, wearable devices, telehealth platforms, artificial intelligence (AI) applications, and electronic health records have changed healthcare delivery through improving access, efficiency, and participation of patients. Regulatory affairs will have an essential part in assuring the safety, effectiveness, quality, and data security of digital health innovations as they expand and grow fast. By influencing how we classify products, evaluate risk, clinically validate, secure cybersecurity, improve interoperability, and evaluate post-market regulatory pathways, we seek to find a balance between innovation and patient safety. Keywords: Artificial Intelligence (AI), Mobile Health, Quality Assurance

ABSTRACTThe Digital Twin (DT), defined as a high-fidelity, real-time virtual representation of a physical system, is poised to revolutionize the pharmaceutical industry. DTs directly address critical challenges-including prolonged development timelines, substantial R&D expenditure, and the inherent limitations of resource-intensive physical experimentation-by enabling real-time simulation, prediction, and optimization across the entire drug lifecycle. DT functionality is predicated on the synergistic integration of advanced technologies, including the Internet of Things (IoT) for ubiquitous data acquisition, Artificial Intelligence (AI)/Machine Learning (ML) for complex predictive modeling, Big Data Analytics, and Cloud Computing for scalable computational power. This technological confluence facilitates predictive modeling and data-driven decision-making, resulting in demonstrable improvements in efficiency, accuracy, and cost-effectiveness. Key applications of DTs span the pharmaceutical workflow: from simulating drug-target interactions in drug discovery and optimizing Critical Process Parameters (CPPs) in formulation development, to enhancing process optimization and predictive maintenance in manufacturing and adherence to Quality by Design (QbD) principles. Despite the vast potential, significant barriers to widespread adoption include challenges related to data integration, the establishment of clear regulatory frameworks, and the computational complexity inherent in creating high-fidelity, multi-scale models. Nevertheless, the integration of DTs represents a cornerstone technology for the future of Pharmaceutical 4.0, promising to drive innovation, reduce time-to-market, and facilitate the development of more personalized and efficient therapeutic modalities. Keywords: Digital Twins (DTs), Pharmaceutical development, Drug discovery, Artificial Intelligence (AI), Machine Learning (ML).